Shares in Oxford BioMedica fell 15% today despite a recent positive half-year trading update. In early August, the MedTech said H1 2026 revenues had grown 9% to approximately £80 million. That followed the rejection of several takeover offers from Swedish private equity firm EQT for the cell and gene therapy developer. However Oxford Biomedica, founded … Continue reading Oxford BioMedica shares fall 15% in one day